FIELD: chemistry of peptides, medicine.
SUBSTANCE: invention relates to preparing new peptides possessing immunomodulating, anti-proliferative, anti-tumor and antiviral activity. Invention proposes new peptides comprising up to 30 amino acid residues of the general structural formula: X1-Trp-Gly-Gln-X2 wherein X1 is taken among the following group: -His-Gly-Val-Ser-Gly-, -His-Gly-Gly-Gly-, -His-Val-Gly-Gly-, -His-Gly-Gly-Gly-Gly-, and -Gln-Gly-Gly-Gly-Gly, or absent; X2 is taken among the following group: -His-Gly-Thr-His-Gly, -Gly-Gly-Thr-His-Gly, -Pro-His-Val-Gly-Gly, -Pro-His-Gly-Gly-Gly, -Pro-His-Gly-Gly-Gly-Trp-Gly, -Gly-Gly-Gly-Thr-His-Ser, or absent.
EFFECT: valuable medicinal properties of peptides.
8 cl, 5 tbl, 5 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR EXTERNAL APPLICATION, POSSESSING ANTIVIRAL ACTIVITY | 2006 |
|
RU2338553C2 |
| METHOD FOR ACTIVATION OF CYTOTOXIC LYMPHOCYTES | 2019 |
|
RU2751837C2 |
| ALLOPHERONES AS IMMUNOMODULATING PEPTIDES | 1999 |
|
RU2172322C1 |
| BIOLOGICALLY ACTIVE PEPTIDES | 2013 |
|
RU2575069C2 |
| BIOLOGICALLY ACTIVE PEPTIDE COMPLEXES | 2011 |
|
RU2470031C2 |
| TARGETED TGF BETA INHIBITION | 2015 |
|
RU2752424C2 |
| MESOTHELINIC CAR RECEPTORS AND USE THEREOF | 2020 |
|
RU2822193C2 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| COMPOSITION FOR TREATING CANCER, COMBINING ANTI-CD26 ANTIBODY AND OTHER ANTI-CANCER AGENT | 2016 |
|
RU2742953C2 |
